Like many other companies and institutions around the world, we are experiencing interference with some of our systems within the TNT network.
We are implementing remediation steps as quickly as possible. We have implemented operational contingencies to continue to complete collections from customers with scheduled stops. For customers who do not have a regular stop, collection should be arranged via our customer service centers.
Customers may experience delays in the transit of shipments, particularly inter-continental or non-EU European delivery, as we work to remediate our systems. Additionally, if customers do not have the facility for self-labeling, they may also experience delays.
We are not able to collect shipments of dangerous goods at this time.
We regret any inconvenience to our customers.
Ensuring Quality from Development to Commercialisation
Our manufacturing operations have been built and designed around the concept of enabling scalability, ensuring we have superior integration of all technologies. From non-GMP to GMP development, to clinical supply, through to commercialisation, we can ensure ease of transfer and scientific continuity.
From the outset, our development scientists strive to develop robust formulations and processes that are suitable for scale-up and large-scale commercialisation. With both the development and commercial teams working closely together on a single site, the result is a smooth project management process and continuation of scientific knowledge.